Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists

“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.

Read the full article here

Related Articles